key: cord-0770084-63skxggd
authors: Compagnone, Nicola; Palumbo, Diego; Cremona, George; Vitali, Giordano; De Lorenzo, Rebecca; Calvi, Maria Rosa; Del Prete, Andrea; Baiardo Redaelli, Martina; Calamarà, Sabrina; Belletti, Alessandro; Steidler, Stephanie; Conte, Caterina; Zangrillo, Alberto; De Cobelli, Francesco; Rovere‐Querini, Patrizia; Monti, Giacomo
title: Residual lung damage following ARDS in COVID‐19 ICU survivors
date: 2021-11-17
journal: Acta Anaesthesiol Scand
DOI: 10.1111/aas.13996
sha: bc038288b593eb08434f392be0a2bc22c12037b0
doc_id: 770084
cord_uid: 63skxggd

BACKGROUND: Coronavirus disease 2019 acute respiratory distress syndrome (COVID‐19 ARDS) is a disease that often requires invasive ventilation. Little is known about COVID‐19 ARDS sequelae. We assessed the mid‐term lung status of COVID‐19 survivors and investigated factors associated with pulmonary sequelae. METHODS: All adult COVID‐19 patients admitted to the intensive care unit from 25th February to 27th April 2020 were included. Lung function was evaluated through chest CT scan and pulmonary function tests (PFT). Logistic regression was used to identify predictors of persisting lung alterations. RESULTS: Forty‐nine patients (75%) completed lung assessment. Chest CT scan was performed after a median (interquartile range) time of 97 (89–105) days, whilst PFT after 142 (133–160) days. The median age was 58 (52–65) years and most patients were male (90%). The median duration of mechanical ventilation was 11 (6–16) days. Median tidal volume/ideal body weight (TV/IBW) was 6.8 (5.71–7.67) ml/Kg. 59% and 63% of patients showed radiological and functional lung sequelae, respectively. The diffusion capacity of carbon monoxide (DL(CO)) was reduced by 59%, with a median per cent of predicted DL(CO) of 72.1 (57.9–93.9) %. Mean TV/IBW during invasive ventilation emerged as an independent predictor of persistent CT scan abnormalities, whilst the duration of mechanical ventilation was an independent predictor of both CT and PFT abnormalities. The extension of lung involvement at hospital admission (evaluated through Radiographic Assessment of Lung Edema, RALE score) independently predicted the risk of persistent alterations in PFTs. CONCLUSIONS: Both the extent of lung parenchymal involvement and mechanical ventilation protocols predict morphological and functional lung abnormalities months after COVID‐19.

The ongoing coronavirus 2019 (COVID-19) pandemic has caused substantial morbidity and mortality worldwide. According to data from the World Health Organization (WHO), by 18 June 2021, the total number of cases globally reached 177.108.695 1 with an overall cumulative death of around 3.840.223.

Although it is in most cases a self-limited respiratory tract illness, COVID-19 may cause acute respiratory distress syndrome (ARDS) requiring invasive ventilation, shock and multi-organ failure. [2] [3] [4] The short-term mortality of invasively ventilated ARDS COVID-19 patients is between 30% and 70% depending on the different setting. [5] [6] [7] Similar to severe acute respiratory syndrome coronavirus (SARS-CoV-1) infection, SARS-CoV-2 infection triggers dysregulated immune-mediated processes that can lead to anatomical damage and fibrosis, influencing lung morphology and function beyond acute disease. [8] [9] [10] [11] [12] In addition to infection-related events, the increased mechanical stress caused by both prolonged positive pressure mechanical ventilation may cause a direct mechanical insult, contributing to lung injury. Similarly, the intense inspiratory efforts by spontaneously breathing patients may also cause self-inflicted lung injury. 13, 14 However, little is known on the respiratory function in COVID-19-related ARDS survivors.

In this paper, we assessed the lung status of COVID-19 survivors after discharge from the intensive care unit (ICU) and identified the predictors of pulmonary dysfunction identified in this patient population.

This investigation is part of the COVID-BioB study carried out at the San Raffaele University Hospital in Milan, Italy to identify predictors of COVID-19 severity, mortality and treatment response and to identify subgroups of patients that might benefit from specific therapeutic interventions. The study methodology has been described. 3, 4, 15, 16 The study comprises, in addition to a thorough assessment of COVID-19 patients at hospital admission, the follow-up in a dedicated outpatient clinic of survivors at 4, 12 and 24 weeks after discharge. 17, 18 The study was approved by the hospital Ethics Committee (protocol No. 34/int/2020) and was registered on ClinicalTrials.gov (NCT04318366). Adult patients with confirmed SARS-CoV-2 infection (defined as positive real-time reverse-transcriptase polymerase chain reaction from a nasal and/ or throat swab along with signs, symptoms and radiological findings suggestive of COVID-19 pneumonia) were admitted to an ICU at the San Raffaele Scientific Institute for ARDS between 25 February and 27 April 2020 received at least one day of invasive ventilation and were discharged before 10 June were included. Demographical data, including age, gender and ethnicity, comorbidities, body mass index (BMI), clinical and laboratory presentation of COVID-19 were assessed. 19 Preliminary analysis of radiological results at hospital admission of COVID-BioB patients has been published. [19] [20] [21] [22] The patients were managed according to recommendations on protective mechanical ventilation and pharmacological treatment of ARDS. 19 After the discharge from the ICU, previously mechanically ventilated COVID-19 patients were evaluated at the COVID19 Follow-up Outpatient Clinic of the San Raffaele University Hospital and offered radiological and functional follow-up.

The primary outcomes were the detection of residual abnormalities at CT scans, defined as the evidence of more than 20% of lung involvement and/or high-resolution CT (HRCT) Score >8, as well as abnormal pulmonary function tests (PFT) defined by either restrictive abnormalities (FVC<80%+FEV1/FVC>70 or TLC <80%), obstructive abnormalities (FEV1/FVC <0.7 or FEV1/FVC% <88% of predicted value) or reduced diffusing capacity of the lungs for carbon monoxide (DLCO-SB) <75% three months after the discharge of COVID-19 survivors from the ICU.

All follow-up CT examinations were performed on a 64-row multidetector CT scanner (SOMATOM Definition Flash Dual Source CT, Siemens Healthcare). CT protocol included an unenhanced, breathhold axial scan of the thorax (from lung apex to the lowest hemidiaphragm); if any concern existed about air trapping, 23 an expiratory scan was also performed.

Two experienced radiologists, both blinded to patients' eventual symptoms, independently reviewed all CT images for fibrotic-like K E Y W O R D S acute respiratory distress syndrome, chest CT scan, COVID-19, critically ill patients, follow-up, intensive care, pulmonary fibrosis, pulmonary function tests

This study shows that there is a high prevalence of lung sequelae in survivors from COVID-19 ARDS, as observed in this cohort. More studies are needed to identify the best strategy to prevent residual lung damage in ICU survivors. changes (honeycombing, reticulation and traction bronchiectasis); 23 differences in the assessment were resolved with consensus.

Furthermore, the quantitative residual burden of ground-glass opacities (GGO), consolidation and fibrotic-like changes (honeycombing, reticulation, traction bronchiectasis) were systematically assessed using a pure quantitative scoring system ranging from 0 to 25 points, which has been previously used, in a semiquantitative mode, for similar purposes. 24 Each pulmonary lobe was assigned 0-5 points on the basis of the volume involved (0 if normally aerated lung parenchyma, 1 if disease burden <5%, 2 if disease burden up to 25%, 3 if up to 50%, 4 if up to 75%, 5 if disease burden >75%). Individual lobar scores were added together as a total patient score. For the main outcome interpretation of CT scan, the identified threshold of 20% of lung involvement and/or high-resolution CT (HRCT) Score >8 was chosen according to the median value in our own population.

The PFTs were performed and interpreted according to the American Thoracic Society (ATS) and European Respiratory Society (ERS) guidelines and ATS/ERS 2005 interpretation standards. 25, 26 All PFTs were conducted using Jaeger MasterScreen PFT Analyzer Unit (JLAB software version 5.3.0, CareFusion, Italy). Spirometry was measured using a pneumotachograph to measure forced vital capacity (FVC) and forced expiration volume at 1 s (FEV 1 ). FEV 1 /FVC was calculated for all patients. The helium washout technique was used to obtain total lung capacity (TLC) and residual volume (RV).

Simultaneous measurement of Transfer factor for carbon monoxide and nitric oxide DLCO/DLNO was measured by single breath technique (SBDLCO) obtaining values for DLCO, DLCO to alveolar volume ratio (DLCO/VA).

Prior to analysis, data were cross-checked with medical charts and verified by data managers and clinicians for accuracy. Categorical variables were expressed as counts (percentage) and continuous variables as medians (interquartile range). Comparisons between groups were performed using the χ2 test or Fisher's exact test for categorical variables, and the Mann-Whitney U test for continuous variables. Univariable and multivariable logistic regression analyses were employed to identify predictors of CT scan and/or PFT abnormalities among all available variables. The results of these analyses were graphically represented in forest plots. Missing data was not imputed. All statistical analyses were performed using R statistical package (version 4.0.0, R Foundation for Statistical Computing, Vienna, Austria), with a two-sided significance level set at p < 0.05. (Table 3) .

Overall, the majority of patients of ARDS survivors had pulmo- (Table 1 ).

In contrast, the length of stay in ICU and total hospital length of stay were significantly different (9 vs. 13 days, p = 0.02; 8 vs. 16.5 days, p = 0.001). Time on invasive mechanical ventilation were also significantly higher (8 vs. 13 days, p = 0.028; 6 vs. 14.5 days, p = 0.001).

LDH and RALE score on presentation in the emergency department were significantly higher in patients with altered PFT, but not in patients with altered lung CT-scan (343 vs. 510 U/L, p = 0.8; 5 vs. 14, p = 0.9) ( Table 1) . Mean TV/IBW was higher in patients with altered lung CT-scan at the follow up (6.2 vs 7.2 mL/kgIBW, p = 0.004) but not for patients presenting with abnormal PFT. There were no differences observed in maximum PEEP, days of pronation and tracheostomy. Patients with or without pulmonary sequelae did not differ in terms of treatment with anti-cytokine agents (anakinra or tocilizumab), antiviral agents or corticosteroids ( Table 2) . 

Radiological evidence of more than 20% of lung involved and/or HRCT score >8 was observed in 59% of patients, whilst restrictive ventilatory defects, and/or DLCO abnormalities, albeit mild, were found in 63% of patients at 3 months after ICU discharge indicating that viral clearance and clinical recovery do not reflect complete lung restitutio ad integrum.

Our findings are in agreement with those from previous studies reporting a high prevalence of CT abnormalities in COVID-19

survivors at three months since discharge from an ICU. [28] [29] [30] [31] Lerum and colleagues reported a low prevalence of PFT abnormalities in patients discharged from ICU (nearly 10%). 28 However, they included only 9 patients ventilated invasively out of a total cohort of 15 patients. In another case series, 29 nearly 40% of COVID-19 survivors had abnormal PFT after approximately 6 weeks following discharge from ICU discharge, whilst Truffaut and colleagues reported 55% of PFT abnormality. 30 A much higher prevalence of PFT abnormalities, (nearly 90%), was observed by van Gassel et al, 31 possibly reflecting a longer duration of invasive mechanical ventilation and higher ICU length of stay. In line with our findings, the most frequent functional anomaly observed in all these studies was impaired DLCO, followed by restrictive impairment. Impaired DLCO was also observed in SARS and Middle East Respiratory Syndrome (MERS) survivors and persisted at 12 months in 11-45% of patients. In these conditions, PFTs improved with time. [31] [32] [33] In patients with ARDS due to other causes treated in the ICU, long-term radiological lung abnormalities including reticular pattern and ground-glass opacities are frequent findings. The percentage of abnormal lung parenchyma decreases over time, being less than 10% at one year after ARDS. A similar tendency is generally observed for PFTs, which indicates a good recovery in terms of lung volume at six months. 34 Conversely, impaired DLCO remains the most frequently impaired lung function test, in an average of 80% of patients after 1 year sometimes lingering even up to five years after ARDS. 35, 36 In our cohort, the number of days on mechanical ventilation independently predicted the presence at follow-up of both radiological and functional pulmonary abnormalities. This is in accordance with studies reporting the length of mechanical ventilation during ICU stay as a factor associated with the severity of lung damage at CT scan at three months in COVID-19 survivors. 37 An inverse correlation between the duration of ventilation and DLCO at 4 months after ICU discharge has also been reported. 38 Longer time on mechanical ventilation may reflect an increased need for ventilatory support due to more severe pneumonia. Therefore, it remains to be clarified whether the higher risk of persistent pulmonary sequelae derives from direct ventilator-mediated mechanisms or is an indirect consequence of a more aggressive underlying disease. The latter is supported by the finding that higher RALE scores predicted altered PFTs, indicating that more extensive lung involvement may be associated with a longer time to recovery or possibly with persistent lung function impairment.

High tidal volumes in patients with ARDS lead to ventilatorinduced lung injury and increased mortality. 39 F I G U R E 3 Axial chest tomography scans of three patient acquired (a, b, c) during the acute phase of the disease (bilateral ground glass opacities predominantly in subpleural locations together with consolidations in the lower lobes, thickened interlobular septa [b]) and (d, e, f) three months after intensive care unit discharge (residual subpleural reticular thickening)

We observed a high prevalence of radiological or functional lung 

All the authors have disclosed that they do NOT have any conflicts of interest or source of funding.

https://orcid.org/0000-0003-3131-0565

Giacomo Monti https://orcid.org/0000-0002-3885-9238

COVID-19) Dashboard

Characteristics and outcomes of 21 Critically Ill patients With COVID-19 in Washington State

Early predictors of clinical outcomes of COVID-19 outbreak in

Characteristics, treatment, outcomes and cause of death of invasively ventilated patients with COVID-19 ARDS in

Clinical characteristics and day-90 outcomes of 4244 critically ill adults with COVID-19: a prospective cohort study

Risk factors associated with mortality among patients with COVID-19 in intensive care units in Lombardy, Italy

Hospital mortality in mechanically ventilated COVID-19 patients in Mexico

The spectrum of pathological changes in severe acute respiratory syndrome (SARS)

Healing after COVID-19: are survivors at risk for pulmonary fibrosis?

Long-term respiratory and neurological sequelae of COVID-19

Severe acute respiratory syndrome-associated coronavirus nucleocapsid protein interacts with Smad3 and modulates transforming growth factor-β signaling

Molecular biology of the SARS-coronavirus

Spontaneous breathing, transpulmonary pressure and mathematical trickery

Caution about early intubation and mechanical ventilation in COVID-19

Biobanking for COVID-19 research

COVID-19 is associated with clinically significant weight loss and risk of malnutrition, independent of hospitalisation: A post-hoc analysis of a prospective cohort study

Residual clinical damage after COVID-19: a retrospective and prospective observational cohort study

Post-COVID-19 follow-up clinic: depicting chronicity of a new disease

Predictors of Pneumothorax/Pneumomediastinum in mechanically ventilated COVID-19 patients

Pulmonary vascular thrombosis in COVID-19 pneumonia

Pneumothorax/pneumomediastinum in non-intubated COVID-19 patients: differences between first and second Italian pandemic wave

Robust prediction of mortality of COVID-19 patients based on quantitative, operatorindependent, lung CT densitometry

Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper

Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery

Standardization of spirometry 2019 update. An official American Thoracic Society and European Respiratory Society Technical Statement

Official ERS technical standards: Global Lung Function Initiative reference values for the carbon monoxide transfer factor for Caucasians

Initial chest radiographs and artificial intelligence (AI) predict clinical outcomes in COVID-19 patients: analysis of 697 Italian patients

lung function and CT findings 3 months after hospital admission for COVID-19

Post-ICU COVID-19 Outcomes

Post-discharge critical COVID-19 lung function related to severity of radiologic lung involvement at admission

High prevalence of pulmonary sequelae at 3 months after hospital discharge in mechanically ventilated survivors of COVID-19

Long-term clinical outcomes in survivors of severe acute respiratory syndrome and Middle East respiratory syndrome coronavirus outbreaks after hospitalisation or ICU admission: a systematic review and meta-analysis

The 1-year impact of severe acute respiratory syndrome on pulmonary function, exercise capacity, and quality of life in a cohort of survivors

What's next after ARDS: longterm outcomes

Radiologic outcomes at 5 years after severe ARDS

Pulmonary function and health-related quality of life in survivors of acute respiratory distress syndrome

Pulmonary function and radiologic features in survivors of critical COVID-19

Pulmonary function and radiological features 4 months after COVID-19: first results from the national prospective observational Swiss COVID-19 lung study

Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome

Ventilator-induced lung injury

Effect of mechanical ventilation on inflammatory mediators in patients with acute respiratory distress syndrome

Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy

Stem cell therapy for COVID-19, ARDS and pulmonary fibrosis

Persistent post-COVID-19 interstitial lung disease. an observational study of corticosteroid treatment